Id: acc0215
Group: 2sens
Protein: STAT2
Gene Symbol: STAT2
Protein Id: P52630
Protein Name: STAT2_HUMAN
PTM: phosphorylation
Site: Tyr690
Site Sequence: KVNLQERRKYLKHRLIVVSNR
Disease Category: Cancer
Disease: Medulloblastoma
Disease Subtype:
Disease Cellline: TE671
Disease Info:
Drug: ISG15 OV
Drug Info: "Pembrolizumab is a humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, used in the treatment of various cancers including melanoma, non-small cell lung cancer, and classical Hodgkin lymphoma. Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor used for the treatment of ovarian, breast, pancreatic, and prostate cancers with specific genetic mutations, such as BRCA1/2."
Effect: modulate
Effect Info: "Overexpression of ISG15 reduces the phosphorylation levels of JAK1 (Tyr701), Tyk2 (Tyr1054/1055), STAT2 (Tyr690), and STAT5 (Tyr694) in JEV-infected cells."
Note: Non-conventional drugs
Score: 3.0
Pubmed(PMID): 20035788
Sentence Index:
Sentence:

Sequence & Structure:

MAQWEMLQNLDSPFQDQLHQLYSHSLLPVDIRQYLAVWIEDQNWQEAALGSDDSKATMLFFHFLDQLNYECGRCSQDPESLLLQHNLRKFCRDIQPFSQDPTQLAEMIFNLLLEEKRILIQAQRAQLEQGEPVLETPVESQQHEIESRILDLRAMMEKLVKSISQLKDQQDVFCFRYKIQAKGKTPSLDPHQTKEQKILQETLNELDKRRKEVLDASKALLGRLTTLIELLLPKLEEWKAQQQKACIRAPIDHGLEQLETWFTAGAKLLFHLRQLLKELKGLSCLVSYQDDPLTKGVDLRNAQVTELLQRLLHRAFVVETQPCMPQTPHRPLILKTGSKFTVRTRLLVRLQEGNESLTVEVSIDRNPPQLQGFRKFNILTSNQKTLTPEKGQSQGLIWDFGYLTLVEQRSGGSGKGSNKGPLGVTEELHIISFTVKYTYQGLKQELKTDTLPVVIISNMNQLSIAWASVLWFNLLSPNLQNQQFFSNPPKAPWSLLGPALSWQFSSYVGRGLNSDQLSMLRNKLFGQNCRTEDPLLSWADFTKRESPPGKLPFWTWLDKILELVHDHLKDLWNDGRIMGFVSRSQERRLLKKTMSGTFLLRFSESSEGGITCSWVEHQDDDKVLIYSVQPYTKEVLQSLPLTEIIRHYQLLTEENIPENPLRFLYPRIPRDEAFGCYYQEKVNLQERRKYLKHRLIVVSNRQVDELQQPLELKPEPELESLELELGLVPEPELSLDLEPLLKAGLDLGPELESVLESTLEPVIEPTLCMVSQTVPEPDQGPVSQPVPEPDLPCDLRHLNTEPMEIFRNCVKIEEIMPNGDPLLAGQNTVDEVYVSRPSHFYTDGPLMPSDF

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

STAT2-Ser187
Cancer Intensity
BRCA 0.707
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC -0.707
non_ccRCC
PDAC
UCEC
STAT2-Ser595
Cancer Intensity
BRCA
COAD
HGSC 0.707
ccRCC
GBM -0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
STAT2-Thr800
Cancer Intensity
BRCA 0.124
COAD
HGSC 0.296
ccRCC -1.895
GBM 1.461
HNSC 0.661
LUAD 0.506
LUSC 0.079
non_ccRCC -1.458
PDAC -0.287
UCEC 0.514

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
T 385 D Melanoma Phosphorylation 31843895
S 381 D Melanoma Phosphorylation 31843895
S 393 D Melanoma Phosphorylation 31843895
- - D Melanoma Ubiquitination 31843895
T 404 U Lung cancer Phosphorylation 37036972

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: